Survodutide
Shop Survodutide on KimeraChems · code GUIDE (10% off)Definition
Survodutide (also known as BI-456906) is a dual-agonist peptide that targets both GLP-1 receptors and glucagon receptors, creating a unique metabolic research profile. It was originally developed by Zealand Pharma in partnership with Boehringer Ingelheim and is currently one of the strongest incretin/glucagon dual-pathway compounds under investigation.
Available Formats
- 10mg lyophilized peptide
Mechanism of Action
Survodutide activates two major metabolic pathways: GLP-1 Receptor Agonism Research models suggest it may: Glucagon Receptor Agonism This pathway is associated with: The combination is designed to balance satiety with increased caloric burn, making survodutide one of the most powerful dual-agonists studied to date.
- Reduce appetite
- Slow gastric emptying
- Improve glucose tolerance
- Stabilize blood sugar
- Decrease caloric intake
- Increased energy expenditure
- Enhanced thermogenesis
- Elevated fat-oxidation
- Increased mobilization of stored fuel
- Improved metabolic rate compared to GLP-1 alone
Areas of Investigation
Survodutide is commonly studied in research settings for
- Obesity and metabolic disorder models
- Body-weight regulation
- Glucose homeostasisLiver-fat reduction (notably in NASH/NAFLD models)
- Energy-expenditure pathways
- Thermogenic signaling
- Dual-receptor agonist synergy models
Safety Profile
Documented in preclinical studies: These findings are consistent with GLP-1/glucagon dual-agonists.
- Nausea during early titration
- Decreased appetite
- Delayed gastric emptying
- GI slowdown or constipation
- Occasional mild increases in HR
- Transient fatigue
- Possible dehydration with large caloric deficits
For educational purposes only. Not for human consumption.